DelveInsight’s, “Epilepsy Pipeline Insight, 2023” report provides comprehensive insights about 75+ companies and 90+ pipeline drugs in the Epilepsy pipeline landscape. It covers the Epilepsy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Epilepsy Pipeline Report
- DelveInsight’s Epilepsy pipeline report depicts a robust space with 75+ active players working to develop 90+ pipeline therapies for Epilepsy treatment.
- The leading companies working in the Epilepsy market include UCB, SK Life Science, Stoke Therapeutics, Xenon Pharmaceuticals, Epygenix, Bright Minds Biosciences, Neurona Therapeutics, Cevevel Therapeutics, PTC Therapeutics, Addex Pharmaceuticals, Equilibre Biopharmaceuticals B.V., ES Therapeutics Australia Pty Ltd, Overseas Pharmaceuticals, Anavex Life Sciences, Eliem Therapeutics, Ovid Therapeutics, CAMP4 Therapeutics, LifeSplice, Virpax Pharmaceuticals, Neuroene Therapeutics, and others.
- Promising Epilepsy Pipeline Therapies in the various stages of development include topiramate, Lacosamide, Levetiracetam, UCB0942, Intravenous Carbamazepine (IV CBZ), Diazepam Buccal Film, XEN1101, and others.
- March 2023: ES Therapeutics Australia Pty Ltd announced a study of Phase 2 clinical trials for ES-481 and Open-Label Extension Study. This is a Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study with cross-over to Evaluate the Efficacy, Safety, and Pharmacokinetics of ES-481 in Adult Patients with Drug Resistant Epilepsy. A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ES-481 in Adult Patients With Drug Resistant Epilepsy.
- October 2023: UCB Biopharma SRL announced a study of Phase 3 clinical trials for Brivaracetam Film-coated tablet. The purpose of the study is to investigate the long-term safety, tolerability and efficacy of brivaracetam in pediatric study participants with childhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE).
Request a sample and discover the recent advances in Epilepsy Treatment Drugs @ Epilepsy Pipeline Report
The Epilepsy pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Epilepsy drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Epilepsy clinical trial landscape.
Epilepsy Overview
Epilepsy is one of the most common serious brain conditions, affecting over 50 million people worldwide. Epilepsy is a neurological disorder that is characterized by an enduring predisposition to generate epileptic seizures and the associated cognitive, psychological, and social consequences.
Find out more about Epilepsy Treatment Drugs @ Drugs for Epilepsy Treatment
Epilepsy Emerging Drugs Profile
- ZX008 (Fenfluramine Hydrochloride): UCB
- Cenobamate: SK Life Science, Inc.
- STK-001: Stoke Therapeutics
- EPX-100: Epygenix
- NRTX-1001: Neurona Therapeutics
- BMB-101: Bright Minds Biosciences
Epilepsy Pipeline Therapeutics Assessment
The Epilepsy pipeline report proffers an integral view of the Epilepsy emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
DelveInsight’s Epilepsy Pipeline report covers around 90+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Epilepsy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Epilepsy Pipeline Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Learn more about the emerging Epilepsy Pipeline Therapies @ Epilepsy Clinical Trials Assessment
Scope of the Epilepsy Pipeline Report
- Coverage- Global
- Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Epilepsy Companies- UCB, SK Life Science, Stoke Therapeutics, Xenon Pharmaceuticals, Epygenix, Bright Minds Biosciences, Neurona Therapeutics, Cevevel Therapeutics, PTC Therapeutics, Addex Pharmaceuticals, Equilibre Biopharmaceuticals B.V., ES Therapeutics Australia Pty Ltd, Overseas Pharmaceuticals, Anavex Life Sciences, Eliem Therapeutics, Ovid Therapeutics, CAMP4 Therapeutics, LifeSplice, Virpax Pharmaceuticals, Neuroene Therapeutics, and others.
- Epilepsy Pipeline Therapies- topiramate, Lacosamide, Levetiracetam, UCB0942, Intravenous Carbamazepine (IV CBZ), Diazepam Buccal Film, XEN1101, and others.
Dive deep into rich insights for new drugs for Epilepsy Treatment, Visit @ Epilepsy Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Epilepsy: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Epilepsy– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- ZX008 (Fenfluramine Hydrochloride): UCB
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- STK-001: Stoke Therapeutics
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- BMB-101: Bright Minds Biosciences
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- NT102: Neuroene Therapeutics
- Drug profiles in the detailed report…..
- Inactive Products
- Epilepsy Key Companies
- Epilepsy Key Products
- Epilepsy- Unmet Needs
- Epilepsy- Market Drivers and Barriers
- Epilepsy- Future Perspectives and Conclusion
- Epilepsy Analyst Views
- Epilepsy Key Companies
- Appendix
For further information on the Epilepsy Pipeline therapeutics, reach out to Epilepsy Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/epilepsy-market